

Farid Saad

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2609700/publications.pdf>

Version: 2024-02-01

101
papers

6,295
citations

57631

44
h-index

66788

78
g-index

103
all docs

103
docs citations

103
times ranked

4499
citing authors

#	ARTICLE	IF	CITATIONS
1	Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. <i>European Journal of Endocrinology</i> , 2013, 168, 829-843.	1.9	343
2	Testosterone and Metabolic Syndrome: A Meta-Analysis Study. <i>Journal of Sexual Medicine</i> , 2011, 8, 272-283.	0.3	310
3	Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blind placebo-controlled Moscow study. <i>Clinical Endocrinology</i> , 2010, 73, 602-612.	1.2	290
4	Fifty-two Week Treatment With Diet and Exercise Plus Transdermal Testosterone Reverses the Metabolic Syndrome and Improves Glycemic Control in Men With Newly Diagnosed Type 2 Diabetes and Subnormal Plasma Testosterone. <i>Journal of Andrology</i> , 2009, 30, 726-733.	2.0	282
5	The Dark Side of Testosterone Deficiency: I. Metabolic Syndrome and Erectile Dysfunction. <i>Journal of Andrology</i> , 2009, 30, 10-22.	2.0	233
6	The Dark Side of Testosterone Deficiency: II. Type 2 Diabetes and Insulin Resistance. <i>Journal of Andrology</i> , 2009, 30, 23-32.	2.0	206
7	The Dark Side of Testosterone Deficiency: III. Cardiovascular Disease. <i>Journal of Andrology</i> , 2009, 30, 477-494.	2.0	204
8	Onset of effects of testosterone treatment and time span until maximum effects are achieved. <i>European Journal of Endocrinology</i> , 2011, 165, 675-685.	1.9	187
9	THERAPY OF ENDOCRINE DISEASE: Testosterone supplementation and body composition: results from a meta-analysis study. <i>European Journal of Endocrinology</i> , 2016, 174, R99-R116.	1.9	171
10	Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. <i>Journal of Endocrinology</i> , 2012, 212, 71-84.	1.2	165
11	Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. <i>International Journal of Clinical Practice</i> , 2014, 68, 314-329.	0.8	158
12	Testosterone supplementation and body composition: results from a meta-analysis of observational studies. <i>Journal of Endocrinological Investigation</i> , 2016, 39, 967-981.	1.8	147
13	Micro-dissected tumor tissues on chip: an ex vivo method for drug testing and personalized therapy. <i>Lab on A Chip</i> , 2016, 16, 312-325.	3.1	141
14	The Aging Males' Symptoms (AMS) scale: update and compilation of international versions. <i>Health and Quality of Life Outcomes</i> , 2003, 1, 15.	1.0	140
15	Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. <i>Obesity</i> , 2013, 21, 1975-1981.	1.5	139
16	Testosterone Partially Ameliorates Metabolic Profile and Erectile Responsiveness to PDE5 Inhibitors in an Animal Model of Male Metabolic Syndrome. <i>Journal of Sexual Medicine</i> , 2009, 6, 3274-3288.	0.3	133
17	The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. <i>Atherosclerosis</i> , 2009, 207, 318-327.	0.4	125
18	Testosterone as Potential Effective Therapy in Treatment of Obesity in Men with Testosterone Deficiency: A Review. <i>Current Diabetes Reviews</i> , 2012, 8, 131-143.	0.6	121

#	ARTICLE	IF	CITATIONS
19	The Aging Males' Symptoms (AMS) scale: review of its methodological characteristics. <i>Health and Quality of Life Outcomes</i> , 2003, 1, 77.	1.0	117
20	Testosterone Therapy in Men With Hypogonadism Prevents Progression From Prediabetes to Type 2 Diabetes: Eight-Year Data From a Registry Study. <i>Diabetes Care</i> , 2019, 42, 1104-1111.	4.3	116
21	A Dose-Response Study of Testosterone on Sexual Dysfunction and Features of the Metabolic Syndrome Using Testosterone Gel and Parenteral Testosterone Undecanoate. <i>Journal of Andrology</i> , 2008, 29, 102-105.	2.0	115
22	Long-Term Testosterone Therapy Improves Cardiometabolic Function and Reduces Risk of Cardiovascular Disease in Men with Hypogonadism. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2017, 22, 414-433.	1.0	109
23	Effects of Testosterone Supplementation on Depressive Symptoms and Sexual Dysfunction in Hypogonadal Men with the Metabolic Syndrome. <i>Journal of Sexual Medicine</i> , 2010, 7, 2572-2582.	0.3	108
24	Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies. <i>International Journal of Obesity</i> , 2016, 40, 162-170.	1.6	103
25	Testosterone Deficiency and Testosterone Treatment in Older Men. <i>Gerontology</i> , 2017, 63, 144-156.	1.4	100
26	Effects of androgen deprivation on glycaemic control and on cardiovascular biochemical risk factors in men with advanced prostate cancer with diabetes. <i>Aging Male</i> , 2007, 10, 189-196.	0.9	92
27	Effects of Long-Term Testosterone Therapy on Patients with "Diabetes": Results of Observational Studies of Pooled Analyses in Obese Hypogonadal Men with Type 2 Diabetes. <i>International Journal of Endocrinology</i> , 2014, 2014, 1-15.	0.6	90
28	Effects of testosterone gel followed by parenteral testosterone undecanoate on sexual dysfunction and on features of the metabolic syndrome. <i>Andrologia</i> , 2008, 40, 44-48.	1.0	88
29	Do Androgens Modulate the Pathophysiological Pathways of Inflammation? Appraising the Contemporary Evidence. <i>Journal of Clinical Medicine</i> , 2018, 7, 549.	1.0	88
30	ORIGINAL RESEARCH"ENDOCRINOLOGY: Improvement of Sexual Function in Men with Late-Onset Hypogonadism Treated with Testosterone Only. <i>Journal of Sexual Medicine</i> , 2007, 4, 497-501.	0.3	86
31	Testosterone Undecanoate Restores Erectile Function in a Subset of Patients with Venous Leakage: A Series of Case Reports. <i>Journal of Sexual Medicine</i> , 2006, 3, 727-735.	0.3	81
32	Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men. <i>Andrologia</i> , 2009, 41, 7-13.	1.0	74
33	Testosterone treatment improves metabolic syndrome-induced adipose tissue derangements. <i>Journal of Endocrinology</i> , 2012, 215, 347-362.	1.2	74
34	An Exploratory Study of the Effects of 12 Month Administration of the Novel Long-Acting Testosterone Undecanoate on Measures of Sexual Function and the Metabolic Syndrome. <i>Archives of Andrology</i> , 2007, 53, 353-357.	1.0	73
35	Improvement of the Metabolic Syndrome and of Non-alcoholic Liver Steatosis upon Treatment of Hypogonadal Elderly Men with Parenteral Testosterone Undecanoate. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2010, 118, 167-171.	0.6	72
36	Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: A pilot study. <i>Aging Male</i> , 2008, 11, 57-61.	0.9	70

#	ARTICLE	IF	CITATIONS
37	Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: An experimental study in the rabbit. <i>Molecular and Cellular Endocrinology</i> , 2014, 384, 143-154.	1.6	70
38	Sex Steroid Receptors in Male Human Bladder: Expression and Biological Function. <i>Journal of Sexual Medicine</i> , 2010, 7, 2698-2713.	0.3	66
39	The Role of Testosterone in the Etiology and Treatment of Obesity, the Metabolic Syndrome, and Diabetes Mellitus Type 2. <i>Journal of Obesity</i> , 2011, 2011, 1-10.	1.1	61
40	Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: An observational study. <i>Obesity Research and Clinical Practice</i> , 2014, 8, e339-e349.	0.8	61
41	Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS - implications for clinical practice. <i>Andrologia</i> , 2006, 38, 1-12.	1.0	60
42	Long-term treatment with testosterone undecanoate injections in men with hypogonadism alleviates erectile dysfunction and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality. <i>Aging Male</i> , 2020, 23, 81-92.	0.9	58
43	Remission of type 2 diabetes following long-term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11-year data from a real-world registry study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2055-2068.	2.2	55
44	Diagnosing and treating testosterone deficiency in different parts of the world. Results from global market research. <i>Aging Male</i> , 2007, 10, 173-181.	0.9	54
45	Effects of intermission and resumption of long-term testosterone replacement therapy on body weight and metabolic parameters in hypogonadal in middle-aged and elderly men. <i>Clinical Endocrinology</i> , 2016, 84, 107-114.	1.2	43
46	Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study. <i>Vascular Health and Risk Management</i> , 2016, 12, 251.	1.0	37
47	Multiple Mechanisms Linking Type 2 Diabetes and Alzheimer's Disease: Testosterone as a Modifier. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 445-466.	1.2	36
48	Mechanisms underlying the metabolic actions of testosterone in humans: A narrative review. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 18-28.	2.2	34
49	Effects of long-term testosterone replacement therapy, with a temporary intermission, on glycemic control of nine hypogonadal men with type 1 diabetes mellitus - a series of case reports. <i>Aging Male</i> , 2015, 18, 164-168.	0.9	33
50	Elderly men over 65 years of age with late-onset hypogonadism benefit as much from testosterone treatment as do younger men. <i>Korean Journal of Urology</i> , 2015, 56, 310.	1.2	32
51	Effects of continuous long-term testosterone therapy (TTh) on anthropometric, endocrine and metabolic parameters for up to 10 years in 115 hypogonadal elderly men: real-life experience from an observational registry study. <i>Andrologia</i> , 2016, 48, 793-799.	1.0	32
52	Androgen therapy in men with testosterone deficiency: can testosterone reduce the risk of cardiovascular disease?. <i>Diabetes/Metabolism Research and Reviews</i> , 2012, 28, 52-59.	1.7	30
53	Differential effects of 11 years of long-term injectable testosterone undecanoate therapy on anthropometric and metabolic parameters in hypogonadal men with normal weight, overweight and obesity in comparison with untreated controls: real-world data from a controlled registry study. <i>International Journal of Obesity</i> , 2020, 44, 1264-1278.	1.6	29
54	Progressive Improvement of T-Scores in Men with Osteoporosis and Subnormal Serum Testosterone Levels upon Treatment with Testosterone over Six Years. <i>International Journal of Endocrinology</i> , 2014, 2014, 1-9.	0.6	26

#	ARTICLE	IF	CITATIONS
55	Testosterone replacement therapy improves the health-related quality of life of men diagnosed with late-onset hypogonadism. Arab Journal of Urology Arab Association of Urology, 2016, 14, 31-36.	0.7	25
56	Testosterone treatment is associated with reduced adipose tissue dysfunction and nonalcoholic fatty liver disease in obese hypogonadal men. Journal of Endocrinological Investigation, 2021, 44, 819-842.	1.8	25
57	Hypogonadal men with moderate-to-severe lower urinary tract symptoms have a more severe cardiometabolic risk profile and benefit more from testosterone therapy than men with mild lower urinary tract symptoms. Investigative and Clinical Urology, 2018, 59, 399.	1.0	20
58	Hypogonadal men with psoriasis benefit from long-term testosterone replacement therapy - a series of 15 case reports. Andrologia, 2016, 48, 341-346.	1.0	19
59	Effects of testosterone on the lower urinary tract go beyond the prostate: New insights, new treatment options. Arab Journal of Urology Arab Association of Urology, 2011, 9, 147-152.	0.7	17
60	Late onset hypogonadism of men is not equivalent to the menopause. Maturitas, 2014, 79, 52-57.	1.0	17
61	Testosterone therapy in men with Crohn's disease improves the clinical course of the disease: data from long-term observational registry study. Hormone Molecular Biology and Clinical Investigation, 2015, 22, 111-117.	0.3	17
62	Testosterone therapy for prevention and reversal of type 2 diabetes in men with low testosterone. Current Opinion in Pharmacology, 2021, 58, 83-89.	1.7	16
63	Is there a relationship between the severity of erectile dysfunction and the comorbidity profile in men with late onset hypogonadism?. Arab Journal of Urology Arab Association of Urology, 2015, 13, 162-168.	0.7	15
64	Long-term testosterone therapy improves liver parameters and steatosis in hypogonadal men: a prospective controlled registry study. Aging Male, 2020, 23, 1553-1563.	0.9	15
65	Dehydroepiandrosterone Treatment in the Aging Male "What Should the Urologist Know?. European Urology, 2005, 48, 724-733.	0.9	14
66	The role of the urologist in the prevention and early detection of cardiovascular disease. Arab Journal of Urology Arab Association of Urology, 2011, 9, 57-62.	0.7	14
67	Dynamic Patterns of Testosterone Levels in Individuals and Risk of Prostate Cancer among Hypogonadal Men: A Longitudinal Study. Journal of Urology, 2018, 199, 465-473.	0.2	11
68	The association of sex hormone-binding globulin with mortality is mediated by age and testosterone in men with type 2 diabetes. Andrology, 2018, 6, 846-853.	1.9	10
69	Testosterone Therapy for Prevention and Treatment of Obesity in Men. Androgens: Clinical Research and Therapeutics, 2020, 1, 40-61.	0.2	8
70	High prevalence of subnormal testosterone in obese adolescent males: reversal with bariatric surgery. European Journal of Endocrinology, 2022, 186, 319-327.	1.9	8
71	Testosterone therapy may reduce prostate cancer risk due to testosterone deficiency at a young age via stabilizing serum testosterone levels. Aging Male, 2020, 23, 112-118.	0.9	7
72	The emancipation of testosterone from niche hormone to multi-system player. Asian Journal of Andrology, 2015, 17, 58.	0.8	7

#	ARTICLE	IF	CITATIONS
73	The relationship between testosterone deficiency and frailty in elderly men. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2010, 4, 529-38.	0.3	6
74	Testosterone Therapy and Glucose Homeostasis in Men with Testosterone Deficiency (Hypogonadism). <i>Advances in Experimental Medicine and Biology</i> , 2017, 1043, 527-558.	0.8	6
75	Administration of testosterone to elderly hypogonadal men with Crohn's disease improves their Crohn's Disease Activity Index: a pilot study. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2010, 2, 287-292.	0.3	5
76	Clinically occult prostate cancer cases may distort the effect of testosterone replacement therapy on risk of PCa. <i>World Journal of Urology</i> , 2019, 37, 2091-2097.	1.2	5
77	Testosterone Deficiency, Long-Term Testosterone Therapy, and Inflammation. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021, 26, 638-647.	1.0	5
78	Age, obesity and inflammation at baseline predict the effects of testosterone administration on the metabolic syndrome. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2011, 6, 193-9.	0.3	4
79	The Author's Reply: Changing testosterone had no direct effect on HbA1c or weight in diabetic men when TRT was interrupted and then resumed. <i>Clinical Endocrinology</i> , 2016, 85, 500-501.	1.2	4
80	Remission of type 2 diabetes and pleiotropic effects of long-term testosterone treatment for late-onset hypogonadism: A case report. <i>SAGE Open Medical Case Reports</i> , 2019, 7, 2050313X1882345.	0.2	4
81	Testosterone Therapy Reduces Cardiovascular Risk Among Hypogonadal Men: A Prospective Cohort Study in Germany. <i>Androgens: Clinical Research and Therapeutics</i> , 2021, 2, 64-72.	0.2	4
82	Cardiovascular Disease, Hypogonadism and Erectile Dysfunction: Early Detection, Prevention and the Positive Effects of Long-Term Testosterone Treatment: Prospective Observational, Real-Life Data. <i>Vascular Health and Risk Management</i> , 2021, Volume 17, 497-508.	1.0	4
83	Remission of type 2 diabetes in a hypogonadal man under long-term testosterone therapy. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2017, 2017, .	0.2	4
84	Examining Male Predominance of Severe COVID-19 Outcomes: A Systematic Review. <i>Androgens: Clinical Research and Therapeutics</i> , 2022, 3, 41-53.	0.2	4
85	Sexual motivation: problem solved and new problems introduced. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2020, 41, .	0.3	3
86	Testosterone Therapy: Increase in Hematocrit is Associated with Decreased Mortality. <i>Androgens: Clinical Research and Therapeutics</i> , 2021, 2, 150-159.	0.2	2
87	Klinefelters Syndrome: Change in <i>T</i> -Scores with Testosterone, Bisphosphonate, and Vitamin D Treatment Over 6 Years. <i>Androgens: Clinical Research and Therapeutics</i> , 2021, 2, 111-120.	0.2	1
88	Design and Conduct of a Real-World Single-Center Registry Study on Testosterone Therapy of Men with Hypogonadism. <i>Androgens: Clinical Research and Therapeutics</i> , 2021, 2, 1-17.	0.2	1
89	P5088 Significant reduction of Framingham risk score in hypogonadal men receiving long-term testosterone therapy: real-life evidence from a 10-year registry. <i>European Heart Journal</i> , 2018, 39, .	1.0	0
90	Effekte der Testosterontherapie auf die Nierenfunktion bei hypogonadalen Männern mit Typ 2 Diabetes (T2DM): Langzeitergebnisse einer urologischen Registerstudie. <i>Diabetologie Und Stoffwechsel</i> , 2021, 16, .	0.0	0

#	ARTICLE	IF	CITATIONS
91	Testosterontherapie führt zu nachhaltigem Gewichtsverlust bei hypogonadalen Männern mit Typ 2 Diabetes (T2DM): Langzeitergebnisse einer urologischen Registerstudie. , 2021, 16, .		0
92	Testosterone Therapy in Adult-Onset Testosterone Deficiency: Hematocrit and Hemoglobin Changes. Androgens: Clinical Research and Therapeutics, 2021, 2, 141-149.	0.2	0
93	Testosterontherapie führt zu Gewichtsverlust und verbesserter glykämischer Kontrolle bei hypogonadalen Männern mit Typ 2 Diabetes (T2DM): 12-Jahres-Langzeitergebnisse einer urologischen Registerstudie. , 2021, 15, .		0
94	Effekte einer Langzeittherapie mit Testosteron auf das Lipidmuster bei Männern mit Hypogonadismus und Adipositas – Beobachtungsdaten einer Registerstudie. Adipositas - Ursachen Folgeerkrankungen Therapie, 2021, 15, .	0.2	0
95	Remission von Typ 2 Diabetes (T2DM) bei 51 von 152 hypogonadalen Männern unter Langzeittherapie mit Testosteron: klinische Beobachtungen aus einer urologischen Registerstudie. , 2019, 14, .		0
96	Nachhaltiger Gewichtsverlust bei hypogonadalen Männern mit Typ 2 Diabetes (T2DM) unter Langzeitbehandlung mit Testosteron: Real-World-Erfahrungen aus einer urologischen Registerstudie. Diabetologie Und Stoffwechsel, 2019, 14, .	0.0	0
97	Verbesserte glykämische Kontrolle und Reduktion von kardiovaskulären Ereignissen und Mortalität bei hypogonadalen Männern mit Typ 2 Diabetes (T2DM) unter Langzeitbehandlung mit Testosteron in einer urologischen Registerstudie. Diabetologie Und Stoffwechsel, 2019, 14, .	0.0	0
98	Langzeitbehandlung mit Injektionen von Testosteron-Undecanoat (TU) führt zu nachhaltigem Gewichtsverlust bei Männern mit Hypogonadismus und Adipositas. Adipositas - Ursachen Folgeerkrankungen Therapie, 2019, 13, .	0.2	0
99	Gewichtsverlust von 24% bei Männern mit Hypogonadismus und Adipositas Klasse III unter Langzeitbehandlung mit Injektionen von Testosteron-Undecanoat (TU). , 2019, 13, .		0
100	Recent testosterone drop-off and risk of cardiovascular events. Aging Male, 2020, 23, 1611-1619.	0.9	0
101	Ist Testosteron-Langzeitbehandlung bei Männern mit Klasse-III-Adipositas eine Alternative zu bariatrischer Chirurgie?. Adipositas - Ursachen Folgeerkrankungen Therapie, 2020, 14, .	0.2	0